The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 10 of the 22 sources its claims cite were checked for support.
The UVA/PADOVA Type 1 Diabetes Simulator: New Features
Open accessAbstract
Recent studies have provided new insights into nonlinearities of insulin action in the hypoglycemic range and into glucagon kinetics as it relates to response to hypoglycemia. Based on these data, we developed a new version of the UVA/PADOVA Type 1 Diabetes Simulator, which was submitted to FDA in 2013 (S2013). The model of glucose kinetics in hypoglycemia has been improved, implementing the notion that insulin-dependent utilization increases nonlinearly when glucose decreases below a certain threshold. In addition, glucagon kinetics and secretion and action models have been incorporated into the simulator: glucagon kinetics is a single compartment; glucagon secretion is controlled by plasma insulin, plasma glucose below a certain threshold, and glucose rate of change; and plasma glucagon stimulates with some delay endogenous glucose production. A refined statistical strategy for virtual patient generation has been adopted as well. Finally, new rules for determining insulin to carbs ratio (CR) and correction factor (CF) of the virtual patients have been implemented to better comply with clinical definitions. S2013 shows a better performance in describing hypoglycemic events. In addition, the new virtual subjects span well the real type 1 diabetes mellitus population as demonstrated by good agreement between real and simulated distribution of patient-specific parameters, such as CR and CF. S2013 provides a more reliable framework for in silico trials, for testing glucose sensors and insulin augmented pump prediction methods, and for closed-loop single/dual hormone controller design, testing, and validation.
Overview
CoChat Summary
TL;DR
The paper presents S2013, a new version of the UVA/PADOVA Type 1 Diabetes Simulator, adding hypoglycemia-aware glucose utilization, glucagon secretion/action, updated joint parameter distributions, and stricter virtual-subject generation. The authors argue that S2013 better describes hypoglycemic events and better matches real CR and CF distributions, while remaining FDA-submitted for preclinical in silico use.
Key findings
- The original S2008 simulator included a population of 300 in silico subjects: 100 adults, 100 adolescents, and 100 children; the paper says S2008 had been used by 32 research groups and reported in 63 peer-reviewed publications.
- S2013 adds a hypoglycemia model with a threshold set at 60 mg/dl and incorporates glucagon kinetics/secretion/action, including a 1-compartment glucagon kinetics model and a 2-compartment subcutaneous glucagon transit model.
- The new simulator was assessed on 32 T1DM subjects in an unpublished clamp dataset and on 13 data sets from 11 adults with T1DM in a bihormonal closed-loop clinical trial; the paper states the model fits glucose data well before the threshold and underestimates data afterward as expected.
- In simulation results for 100 adults, 100 adolescents, and 100 children, the paper reports that the distributions of CR and CF “well reproduce” real patients, and that children had higher CFs than adolescents and adults; the table reports mean weight, insulin needs, CHO ratio, and fasting plasma glucose for each group.
Methods
- The paper is a simulator-development paper comparing S2013 to S2008, describing changes to the glucose-insulin model, counterregulation, parameter distributions, and virtual patient generation.
- It uses simulation and model identification/assessment on two empirical datasets: 32 T1DM subjects undergoing hyperinsulinemic euglycemic and hypoglycemic clamps, and 11 adults with T1DM (13 data sets) from a 27-hour bihormonal closed-loop study with 3 carbohydrate-rich meals.
- Main analyses include fitting the hypoglycemia model, simulating 50 g CHO meal tests for CR estimation, using the 1700 rule for CF, and filtering virtual subjects by CR thresholds, steady-state glucose > 300 mg/dl, and Mahalanobis distance below the 95% percentile.
Limitations
- The authors explicitly state that the subcutaneous glucagon model “suffers some important limitations,” because it was hard to isolate insulin’s effect on glucagon response since insulin is constantly changing, and glucagon is given repeatedly in the study.
- They note that both S2008 and S2013 were validated and accepted by FDA for a single meal scenario only; multiple-meal scenarios can be simulated, but results would not be realistic because the simulator does not include time-varying parameters.
- Evident from the text: the paper repeatedly presents validation and comparison results, but it does not report formal performance metrics such as error estimates, p-values, or confidence intervals for the simulator comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 2 Not valid · 5 Not checked · 24 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The development of artificial pancreas control algorithms in the past few years has been accelerated by computer simulation; for example, in silico testing has provided directions for clinical studies and ruling out of ineffective control scenarios in a cost-effective manner. 1,2”
What the sources say
- Supportedcites [1] source
Section IV.D says in silico testing supported authorization of a clinical trial, helped rule out ineffective control scenarios, and produced preclinical results in a fraction of the time and cost of animal trials. This supports the claim that simulation accelerated artificial-pancreas algorithm development, while the paper cautions that simulation does not replace clinical trials. (LLM, conf=0.93)
- Partly supportedcites [2] sourceExperimental — accuracy not yet measured
In “A step forward: in silico experiments replacing animal trials” (page unavailable), the paper says simulation is already used to test control algorithms efficiently and at a fraction of the time and cost of animal trials. But it says simulation *will* greatly accelerate future artificial-pancreas development; it does not establish that algorithm development had already accelerated in the past few years. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This model was assessed on a clinical data set kindly provided by Dr Damiano's group (Boston University), which was collected in a bihormonal closed-loop clinical trial. 15”
What the sources say
- Could not verifycites [15]Experimental — accuracy not yet measured
The Patients and Methods passages (page not provided) describe insulin-tolerance tests and measurements of glucose and pancreatic glucagon, not an assessment of a subcutaneous glucagon transport model. Searches for the model, Dr. Damiano’s group, and a bihormonal closed-loop trial found no passage addressing the attributed claim. (LLM, conf=0.76)
plainn = 11- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This phenomenon has been described during hyperinsulemic clamps in T1DM. 9,10”
What the sources say
- Partly supportedcites [9] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that, during hyperinsulinemic clamps in patients with type 1 diabetes, a lower glucose nadir was associated with faster model-estimated insulin utilization. It does not describe insulin action increasing within a patient as glucose crosses a particular threshold; the reported association is across subjects. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [10] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The choice to include glucagon secretion was based on our recent data in T1DM 23 showing a nonnegligible glucagon secretion.”
What the sources say
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports measurable plasma glucagon concentrations in people with type 1 diabetes and a postprandial increase that differed by meal. That supports including glucagon in a model, but the paper reports concentrations rather than directly measuring secretion or establishing its magnitude as “nonnegligible.” (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“S2013 shows a better performance in describing hypoglycemic events.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
13 more claims
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the contrary, the Hovorka model and the UVAPadova model were originally formulated to represent the physiological behaviour of T1DM individuals, and no modification is necessary for the purpose of the present work.”
From A comparison among three maximal mathematical models of the glucose-insulin system (2021) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This model is indeed included in the EGP module of the UVa/Padova T1D simulator [32–34].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the Hovorka model and the UVAPadova Simulator only describe the glucose metabolism of a subject with type 1 diabetes, the Sorensen model was formulated to simulate the behaviour of both normal and diabetic individuals.”
From A comparison among three maximal mathematical models of the glucose-insulin system (2021) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The training set, which spanned a wide range of pre-meal conditions and patient characteristics, was created in silico by the UVa/Padova T1D Simulator [38], a simulation tool that includes a model of glucose-insulin-glucagon dynamics in subjects with T1D, accepted by the FDA to substitute preclinical trials of certain insulin treatments.”
From Advanced Diabetes Management Using Artificial Intelligence and Continuous Glucose Monitoring Sensors (2020) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“Another example is compartmental glucose-insulin models, which have been used to generate virtual cohorts to evaluate automated insulin pumps [38,39]”
From Credibility assessment of in silico clinical trials for medical devices (2024) · cites this paper as [38]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ T1DM Simulator 2013 (S2013)
“which was collected in a bihormonal closed-loop clinical trial. 15”
§ References
“15. Lorenzi M, Bohannon N, Tsalikian E, et al. Duration of type 1 diabetes affects glucagon and glucose responses to insulininduced hypoglycemia. West J Med . 1984;141:467-471.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ T1DM Simulator 2013 (S2013)
“only subjects who met the following criteria have been included in the new in silico population: (1) CR ≤ 30 g/U for adult and adolescents and CR ≤ 40 g/U for children”
§ Simulation Results
“| CHO ratio (g/U) | 15.9 (5.3) | 7.2 | 29.5 | 16.0 (5.9) | 5.3 | 32.2 | 23.6 (6.6) | 8.0 | 33.7 |”
Citations
Cites
Quantitative estimation of insulin sensitivity.
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.6.e667 · Cited by 1,874 · cited 1×
“where G(t) is plasma glucose concentration, I(t) is plasma insulin concentration, GIR(t) is exogenous glucose infusion rate, SG, SI, and p 2 are model parameters, and risk is defined as in (11-12).”
BackgroundSelf-citationIn Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes
Kovatchev, B. P., Breton, M., Dalla Man, C., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300106 · Cited by 760
Self-citationArtificial Pancreas: Past, Present, Future
Cobelli, C., Renard, E., & Kovatchev, B. (2011) · Diabetes · doi:10.2337/db11-0654 · Cited by 600
Self-citationDiabetes: Models, Signals, and Control
Cobelli, C., Dalla Man, C., Sparacino, G., Magni, L., De Nicolao, G., & Kovatchev, B. P. (2009) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2009.2036073 · Cited by 511
Self-citationA Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
A Comparison of Childhood and Adult Type I Diabetes Mellitus
Karjalainen, J., Salmela, P. I., Ilonen, J., Surcel, H., & Knip, M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201401 · Cited by 277
Age of Onset and Type of Diabetes
Laakso, M., & Pyörälà, K. (1985) · Diabetes Care · doi:10.2337/diacare.8.2.114 · Cited by 248
Evaluating the Efficacy of Closed-Loop Glucose Regulation via Control-Variability Grid Analysis
Magni, L., Raimondo, D. M., Man, C. D., Breton, M. D., Patek, S. D., Nicolao, G. D., Cobelli, C., & Kovatchev, B. P. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200414 · Cited by 207
Self-citationIncidence of Type 1 and Type 2 Diabetes in Adults Aged 30–49 Years
Bruno, G., Runzo, C., Cavallo‐Perin, P., Merletti, F., Rivetti, M., Pinach, S., Novelli, G., Trovati, M., Cerutti, F., Pagano, G., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2613 · Cited by 195
Closing the Loop: The Adicol Experience
Hovorka, R., Chassin, L. J., Wilinska, M. E., Canonico, V., Akwi, J. A., Federici, M. O., Massi‐Benedetti, M., Hutzli, I., Zaugg, C., Kaufmann, H., et al. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/152091504774197990 · Cited by 153
Research works printed but not linked: 4
- Bergman RN, 1979, Am J Physiol, 236, E667
- Lorenzi M, 1984, West J Med, 141, 467
- Walsh J, Pumping Insulin. Everything You Need for Success with an Insulin Pump, 2000, 105
- Davidson PC, 2003, Diabetes Technol Ther, 5, 237
Cited by
Convolutional Recurrent Neural Networks for Glucose Prediction
Li, K., Daniels, J., Liu, C., Herrero, P., & Georgiou, P. (2019) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2019.2908488 · Cited by 333
In silico clinical trials: how computer simulation will transform the biomedical industry
Viceconti, M., HENNEY, A. M., & Morley‐Fletcher, E. (2016) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20161408 · Cited by 316
The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day
Visentin, R., Campos-Náñez, E., Schiavon, M., Lv, D., Vettoretti, M., Breton, M., Kovatchev, B. P., Dalla Man, C., & Cobelli, C. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818757747 · Cited by 280
“The pulmonary route of administration is described using the model of inhaled insulin pharmacokinetic described in Visentin et al.(34) This model (equations A20, A21) has been identified on 12 T1D subjects, and assumes that a certain fraction of inhaled insulin reaches the alveoli, and then it is rapidly absorbed from…”
MethodSelf-citationA review of personalized blood glucose prediction strategies for T1DM patients
Oviedo, S., Vehí, J., Calm, R., & Armengol, J. (2017) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.2833 · Cited by 279
Deep Learning for Diabetes: A Systematic Review
Zhu, T., Li, K., Herrero, P., & Georgiou, P. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.3040225 · Cited by 294
“The UVA/Padova T1D simulator, developed by the University of Virginia (US) and the University of Padova (Italy), is a glucose-insulin dynamics simulator that has been accepted by the Food and Drug Administration for pre-clinical studies [86].”
Background
Metadata
- Authors
- Man, C. D., Micheletto, F., Lv, D., Breton, M., Kovatchev, B., & Cobelli, C.
- Affiliations
- University of Padua (IT)
- University of Virginia (US)
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2014-01
- Volume
- 8
- Issue
- 1
- Pages
- 26-34
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC4454102
- OpenAlex
- W2129995532
- Cited by
- 791
- References
- 25
- Citations by year
- 2026: 49 · 2025: 85 · 2024: 76 · 2023: 89 · 2022: 69 · 2021: 76 · 2020: 91 · 2019: 77 · 2018: 66 · 2017: 47 · 2016: 30 · 2015: 23 · 2014: 10
- FWCI
- 29.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, hypoglycemia, glucose kinetics, virtual patients, correction factors, in silico clinical trials, artificial pancreas, glucose sensor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The UVA/PADOVA Type 1 Diabetes Simulator: New Features. https://app.cochat.ai/papers/10.1177/1932296813514502
- The paper
- Man, C. D., Micheletto, F., Lv, D., Breton, M., Kovatchev, B., & Cobelli, C. (2014). The UVA/PADOVA Type 1 Diabetes Simulator: New Features. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296813514502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.